O-1918

O-1918
Identifiers
	IUPAC name 1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene;
CAS Number	536697-79-7;
PubChem CID	40469923;
CompTox Dashboard (EPA)	DTXSID10610371 ;
Chemical and physical data
Formula	C19H26O2
Molar mass	286.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C[C@@H](C2=C(OC)C=C(C)C=C2OC)[C@H](C(C)=C)CC1;

O-1918 is a synthetic compound related to cannabidiol, which is an antagonist at two former orphan receptors GPR18 and GPR55, that appear to be related to the cannabinoid receptors. O-1918 is used in the study of these receptors, which have been found to be targets for a number of endogenous and synthetic cannabinoid compounds, and are thought to be responsible for most of the non-CB₁, non-CB₂ mediated effects that have become evident in the course of cannabinoid research.^[1]^[2]^[3]^[4]^[5]

References

^ Offertáler, L.; Mo, F. M.; Bátkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. (2003). "Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor". Molecular Pharmacology. 63 (3): 699–705. doi:10.1124/mol.63.3.699. PMID 12606780.
^ Zakrzeska, A.; Schlicker, E.; Baranowska, M.; Kozłowska, H.; Kwolek, G.; Malinowska, B. (2010). "A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats". British Journal of Pharmacology. 160 (3): 574–584. doi:10.1111/j.1476-5381.2009.00579.x. PMC 2931558. PMID 20105178.
^ Schuelert, N.; McDougall, J. J. (2011). "The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55". Neuroscience Letters. 500 (1): 72–76. doi:10.1016/j.neulet.2011.06.004. PMID 21683763.
^ Szczesniak, A. M.; Maor, Y.; Robertson, H.; Hung, O.; Kelly, M. E. M. (2011). "Nonpsychotropic Cannabinoids, Abnormal Cannabidiol and Canabigerol-Dimethyl Heptyl, Act at Novel Cannabinoid Receptors to Reduce Intraocular Pressure". Journal of Ocular Pharmacology and Therapeutics. 27 (5): 427–435. doi:10.1089/jop.2011.0041. PMID 21770780.
^ Caldwell, M. D.; Hu, S. S. J.; Viswanathan, S.; Bradshaw, H.; Kelly, M. E.; Straiker, A. (2013). "A GPR18-based signaling system regulates IOP in murine eye". British Journal of Pharmacology. 169 (4): 834–43. doi:10.1111/bph.12136. PMC 3687663. PMID 23461720.

[1] Offertáler, L.; Mo, F. M.; Bátkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. (2003). "Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor". Molecular Pharmacology. 63 (3): 699–705. doi:10.1124/mol.63.3.699. PMID 12606780.

[2] Zakrzeska, A.; Schlicker, E.; Baranowska, M.; Kozłowska, H.; Kwolek, G.; Malinowska, B. (2010). "A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats". British Journal of Pharmacology. 160 (3): 574–584. doi:10.1111/j.1476-5381.2009.00579.x. PMC 2931558. PMID 20105178.

[3] Schuelert, N.; McDougall, J. J. (2011). "The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55". Neuroscience Letters. 500 (1): 72–76. doi:10.1016/j.neulet.2011.06.004. PMID 21683763.

[4] Szczesniak, A. M.; Maor, Y.; Robertson, H.; Hung, O.; Kelly, M. E. M. (2011). "Nonpsychotropic Cannabinoids, Abnormal Cannabidiol and Canabigerol-Dimethyl Heptyl, Act at Novel Cannabinoid Receptors to Reduce Intraocular Pressure". Journal of Ocular Pharmacology and Therapeutics. 27 (5): 427–435. doi:10.1089/jop.2011.0041. PMID 21770780.

[5] Caldwell, M. D.; Hu, S. S. J.; Viswanathan, S.; Bradshaw, H.; Kelly, M. E.; Straiker, A. (2013). "A GPR18-based signaling system regulates IOP in murine eye". British Journal of Pharmacology. 169 (4): 834–43. doi:10.1111/bph.12136. PMC 3687663. PMID 23461720.

[1]

[2]

[3]

[4]

[5]

See also

References